Objective: To analyse the therapeutic effects of etanercept (ETA) or adalimumab (ADA) on the numbers and phenotypes of CD4+CD25hi Tregs in RA patients.
Methods: RA patients received ADA (n = 28) or ETA (n = 20) and stable-dose MTX or LEF. Therapeutic responses were assessed with the 28-joint DAS (DAS-28) criteria after 12 weeks of treatment. Treg numbers and phenotypes, determined by flow cytometry using different gating strategies, were compared between responders and non-responders before and after 6 and 12 weeks of treatment.
Results: The percentages of good, moderate and non-responders among patients given ADA or ETA, respectively, were 46.5, 35.7 and 17.8% or 30, 20 and 50%, with respective mean (s.d.) pre-treatment CD4+CD25hi Treg percentages of 5.5 (0.04)% or 4.95 (0.02)%. Overall, for patients with active RA given ADA or ETA, neither TNF-α-blocking agent had an effect on Tregs percentage and absolute number. Moreover, CD4+CD25hi Treg counts remained unaffected in RA responders to ADA or ETA, compared with RA non-responders. Furthermore, the CD4+CD25hiCD45RA+, CD4+CD25hiCD45RO+ and CD4+CD25hiCD62L+ cell populations were unchanged by TNF-α-blocking agents.
Conclusion: Neither ADA nor ETA modified the percentages or absolute numbers of circulating CD4+CD25hi Tregs and their phenotypes after being administered for 6 and 12 weeks to RA patients.
Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00234234.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/ker183 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- - The study evaluated the effectiveness, safety, and immune response of Etanercept (ETA) and Adalimumab (ADA) biosimilars in children with juvenile idiopathic arthritis compared to their original drug versions.
- - After 24 months, children treated with biosimilars showed significantly lower disease activity scores and fewer harmful antibodies compared to those on the original drugs, indicating better treatment outcomes.
- - The safety of biosimilars was similar to the originators, but further research with a larger sample size is necessary to confirm these findings.
An Acceptor-Donor-Acceptor Structured Nano-Aggregate for NIR-Triggered Interventional Photoimmunotherapy of Cervical Cancer.
Adv Mater
September 2024
State Key Laboratory and Institute of Elemento-Organic Chemistry, The Centre of Nanoscale Science and Technology and Key Laboratory of Functional Polymer Materials, Renewable Energy Conversion and Storage Center (RECAST), Tianjin Key Laboratory of Functional Polymer Materials, College of Chemistry, Nankai University, Tianjin, 300071, China.
Compared with conventional therapies, photoimmunotherapy offers precise targeted cancer treatment with minimal damage to healthy tissues and reduced side effects, but its efficacy may be limited by shallow light penetration and the potential for tumor resistance. Here, an acceptor-donor-acceptor (A-D-A)-structured nanoaggregate is developed with dual phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), triggered by single near-infrared (NIR) light. Benefiting from strong intramolecular charge transfer (ICT), the A-D-A-structured nanoaggregates exhibit broad absorption extending to the NIR region and effectively suppressed fluorescence, which enables deep penetration and efficient photothermal conversion (η = 67.
View Article and Find Full Text PDFAdherence, persistence and treatment switching in psoriasis.
Immunotherapy
July 2024
ASL Pescara, Hospital Pharmacy.
Article Synopsis
- This study looks at how often and consistently patients with psoriasis use different drugs over 1 to 5 years, specifically focusing on medications like Adalimumab and others.
- Researchers used real-life data to measure how well patients adhered to their treatment plans using the Proportion of Days Covered (PDC) method.
- While adherence to treatment was generally good, the study found that persistence (the duration patients stay on treatment) dropped significantly after the second year, highlighting the need for better strategies to encourage long-term treatment.
TNF blockers alone and associated with Benznidazole impact in vitro cytokine dynamics in chronic Chagas disease.
Parasite Immunol
February 2024
Instituto Aggeu Magalhães-IAM/Fiocruz, Recife, Pernambuco, Brazil.
Article Synopsis
- Studies on the immune response in Chagas disease show that symptomatic patients, especially those with severe Chagas heart disease, have an inflammatory immune profile dominated by tumour necrosis factor (TNF).
- The research evaluates cytokine levels in patients with different clinical forms of Chagas disease after treatment with TNF blockers (Adalimumab and Etanercept) and benznidazole, measuring the effects on both regulatory and inflammatory cytokines.
- Results indicate that Adalimumab was more effective in blocking TNF, while Etanercept showed a specific decrease in TNF levels only in the most severe cases, suggesting that targeting TNF could be a beneficial strategy for the immunological treatment of severe Chagas heart disease.
Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.
Ophthalmol Ther
March 2024
Department of Medicine, Surgery and Neurosciences, Ophthalmology Unit, ERN RITA Center, Policlinico "Le Scotte", University of Siena, Viale Bracci 16, 53100, Siena, Italy.
Article Synopsis
- Many biological drug patents have expired, leading to the development of biosimilar agents (BIOs), but their use in children raises concerns, prompting a study on their efficacy and safety for treating pediatric non-infectious uveitis (NIU).
- Data collected from pediatric patients treated with TNF inhibitors BIOs showed a significant decrease in flare-ups and ocular complications, as well as a reduction in the need for glucocorticoids during treatment.
- The study included 47 patients, demonstrating strong treatment retention rates and maintaining visual acuity throughout the therapy, while only recording a few minor adverse events.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!